BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

Download PDF Copy

Editorial Checklist

Reviewed

Nov 9 2010

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74^th ACR Scientific Meeting being held in Atlanta, Georgia.

“Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout”

The data will be presented during a poster session scheduled for November 8, 2010 from 9:00-11:00 a.m. Eastern Time. The poster to be presented during the session is entitled:

"Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout". This poster concludes that BCX4208 doses administered at 40, 80, 120, 160 and 240 mg once-daily monotherapy rapidly and significantly reduced serum uric acid (sUA) in patients with gout. BCX4208 was generally safe and well-tolerated at the doses evaluated in this study.

Source:

http://www.biocryst.com/

Posted in: Drug Trial News | Medical Condition News

Tags: Allopurinol, Biotechnology, Burn, Cancer, Efficacy, Gout, Influenza, Nucleoside, Pharmaceuticals, Purine, Rheumatology, Uric Acid

Comments (0)

Download PDF Copy

Suggested Reading

Natural nutrients nicotinamide and pyridoxine reverse muscle aging

Natural nutrients nicotinamide and pyridoxine reverse muscle aging

Breakthrough pig kidney transplant ends dialysis for Alabama woman

Breakthrough pig kidney transplant ends dialysis for Alabama woman

California expanded Medi-Cal to unauthorized residents. The results are mixed.

California expanded Medi-Cal to unauthorized residents. The results are mixed.

Insulin resistance linked to 31 diseases and higher early death risk in women

Insulin resistance linked to 31 diseases and higher early death risk in women

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients

Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients

Comprehensive study highlights effectiveness and limitations of ADHD treatments in adults

Comprehensive study highlights effectiveness and limitations of ADHD treatments in adults

New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk

New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Genetics identified as key factor in gout development